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Abstract
Purpose Chronic kidney disease (CKD) negatively affects
health-related quality of life (HRQoL), which is often mea-
sured using theMedical Outcomes Study Short Form 36 (SF-
36) questionnaire. However, the adequacy of SF-36 in this
population has not been reported. We aimed to determine
floor and ceiling effects and responsiveness to change of SF-
36 in patients with conservatively managed stage 5 CKD.
Methods SF-36 data were collected prospectively. Floor
and ceiling effects were estimated for each SF-36 scale and
summary measure based on raw scores. The minimal
clinically important difference (MCID) was estimated
using a combination of anchor-based and distribution-
based methods. Responsiveness to change was assessed by
comparing MCID for each scale and summary measure to
its smallest detectable change.
Results SF-36 data were available for 73 of the 74 study
participants. Using baseline data, floor and/or ceiling
effects were detected for 3 of the 8 SF-36 scales. The
anchor-based estimation of MCID based on differences in
baseline functional status yielded the most reliable results.
For the physical component summary, MCID was esti-
mated at 5.7 points. Whilst the two SF-36 summary
measures were responsive to change and free of floor and/
or ceiling effects, six of the eight scales were not.
Conclusions This small study of patients with conserva-
tively managed stage 5 CKD found that only the summary
measures of SF-36 and 2 of its 8 scales can be used to
assess changes in HRQoL over time. These findings sug-
gest that in this population, alternative HRQoL assessment
tools should be considered for future studies.
Keywords Chronic kidney diseases  Quality of life  Short
Form 36 Health Survey  Longitudinal studies
Background
The health-related quality of life (HRQoL) of patients with
chronic kidney disease (CKD) is poorer than that of the
general population, both in the early stages of CKD [1–5]
and in advanced (stage 5) disease [6–9]. Stage 5 CKD is
diagnosed when kidney function, measured by the esti-
mated glomerular filtration rate (eGFR), falls below
15 mL/min/1.73 m2 [10]. Its prevalence and incidence in
the developed world are increasing [11–13]. In the UK, for
example, prevalence has increased from 523 per million
population (pmp) in 2000 to 861 pmp in 2012, and inci-
dence rates have increased from 95 pmp in 2001 to
108 pmp in 2012 [11, 12]. In particular, prevalence in the
over 85 age group is rising steeply and nearly doubled
between 2006 and 2012 [11].
Stage 5 CKD is a life-limiting disease for which renal
replacement therapy (RRT) is often recommended. How-
ever, RRT imposes a significant burden on those requiring
it, with implications for the physical and social lives of
patients and their carers [14–16]. The survival advantage of
RRT, and specifically that of dialysis treatment, appears to
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be limited to patients without multi-morbidity [17–23].
Therefore, conservative management of stage 5 CKD is
increasingly offered to selected patients [24], with a focus
on best supportive care, often with input from palliative
care services which actively manage symptoms and pro-
vide holistic care [21, 25].
Most studies of HRQoL in patients with stage 5 CKD
use cross-sectional methods, and the few longitudinal
studies yield conflicting results [6, 7, 15, 26]. Moreover,
most studies focus on dialysis patients; therefore, little is
known about the HRQoL of conservatively managed
patients and its change over time [27, 28]. The interpreta-
tion of any report of HRQoL relies, however, on the
validity and reliability of the tools used.
The Medical Outcomes Study Short Form 36 (SF-36) is
a widely used HRQoL questionnaire which has been
extensively validated in CKD populations, and is com-
monly used either in its original generic form or as part of
the kidney disease quality of life (KDQOL) questionnaire
developed for dialysis patients [29, 30]. SF-36 has also
been used to measure the HRQoL of patients with
advancing disease who are approaching death [7, 26], but
to our knowledge its suitability in this population has not
been tested.
The appropriateness of a HRQoL measurement tool
relies in part on its measurement properties, including floor
and/or ceiling effects and responsiveness to change, and on
its interpretability [31]. Floor and/or ceiling effects are
present when [15 % of the population score lowest or
highest, respectively, on a certain scale [32]. When present,
a tool cannot differentiate between people who may have
had significantly different experiences not captured by
the research tool. Responsiveness to change refers to the
ability of a scale to detect clinically important changes
over time [32]. Interpretability, the degree to which
qualitative meaning can be assigned to quantitative
scores [33] is also vital, because the magnitude and
statistical significance of a reported change do not nec-
essarily correlate with clinical relevance. An advantage
of SF-36 is that as part of its scoring process, individual
scores are compared to a reference (‘normative’) popu-
lation. This facilitates intuitive interpretation of scores
as ‘higher’ or ‘lower’ than average in the general pop-
ulation and enables indirect comparison of normed
results between different studies [34]. In many popula-
tions, SF-36 is regarded sensitive to change, but robust
estimations of its minimal clinically important difference
(MCID) and interpretability are lacking.
The aim of the current study is to estimate floor and
ceiling effects and responsiveness to change of SF-36 in
patients with conservatively managed stage 5 CKD, to
reflect on its appropriateness as a HRQoL measurement
tool in this growing patient population.
Methods
This was a secondary data analysis. We used cross-sec-
tional baseline data available from a primary study con-
ducted by one of the authors (FM) [35]. Primary data were
collected prospectively and longitudinally from partici-
pants recruited from three renal units in London and South-
East England between April 2005 and November 2006. All
three units had dedicated multi-disciplinary services for
conservative management, offering needs-based physical,
psychological and social support. Inclusion criteria were a
diagnosis of stage 5 CKD with a confirmed decision for
conservative management. The only exclusion criterion
was lack of capacity to give consent to participate in the
study. Potential participants were referred to the researcher
(FM) by the clinical teams, following which informed
consent was sought. Continued consent was obtained
monthly by telephone.
One hundred and forty-two people were identified as
potential participants. Of those, 40 were excluded, as
shown in Fig. 1 [36]. Of the 102 remaining patients, 74
consented to participate and formed the final sample for the
study. Clinical characteristics were similar between par-
ticipants and non-participants, as were age and sex. Eth-
nicity was distributed unequally with a higher level of
participation among those from minority ethnic groups as
compared with white patients. Further details of the pri-
mary study were previously reported [35, 37, 38].
Baseline clinical and demographic data were collected
from clinical files. Data regarding HRQoL were collected
at baseline and every 3 months using a postal standard SF-
36 questionnaire, which assesses participants’ HRQoL over
the preceding 4 weeks. Data collection continued until
death, withdrawal from the study or end of study.
Fig. 1 Recruitment flow chart (adapted from the CONSORT flow
diagram [36])
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The primary study had ethical approval from King’s
College Hospital NHS Research Ethics Committee (num-
ber 04-03-092). Specific approval for this further analysis
was waived by the Ethics Committee as it did not diverge
from the original research to which participants consented.
Scoring participants’ responses to SF-36
SF-36 items were coded and scored as outlined in the SF-
36 scoring manual [39]. Briefly, after appropriate recoding
of complete and missing data, raw scores of the 8 scales
[physical functioning (PF), role physical (RP), bodily pain
(BP), general health (GH), vitality (VT), social functioning
(SF), role emotional (RE) and mental health (MH)] were
computed and transformed to a 0–100 scale, with higher
scores representing better HRQoL. Norm-based transfor-
mation was carried out for each scale, and the two sum-
mary measures [physical component summary (PCS) and
mental component summary (MCS)] were computed.
Norm-based scoring yields a distribution of scores in which
scores lower than 50 indicate poorer HRQoL compared to
the reference (‘normative’) population, which in turns
enables a more intuitive interpretation of the impact of the
condition being examined, compared with the reference
population. For this study, data from the Welsh Health
Survey 2007 were used as reference [40, 41].
Selecting a normative population
The study population was an elderly population drawn from
London and South-East England. An ideal normative data set
would be drawn from the same area at the same time, but
include similarly aged patients without CKD or with early-
stage CKD.Unfortunately, such a normative data set was not
available. The Welsh Health Study (WHS), drawn from the
work of Burholt and Nash [40], but originally derived from
the National Centre for Social Research on behalf of the
Welsh AssemblyGovernment [41], was chosen because data
were collected in the UK at a contemporary time period and
included elderly participants. HRQoL is known to be
affected by age, but normative data for elderly participants
are scarce [34]. We aimed to overcome this limitation by
using as reference only WHS data which were derived from
people of similar age to our sample (mean age 80.7 ± 6.8,
median 81.4 and 25th percentile of 78.1). Weighted means
and standard deviations (SDs) were calculated for WHS
participants aged 75 and over. Those means and SDs were
then used to calculate the study normed scores [39]. WHS
data were drawn from a random sample of private house-
holds in Wales. Although not explicitly reported by Burholt
and Nash [40], a potential disadvantage of WHS data was
that ethnicity in this sample was likely to be predominantly
white [42].
Handling of missing data
Missing items and missing questionnaires were differen-
tially coded and reported. Handling of specific SF-36
missing items followed the SF-36 scoring manual [39]. The
manual suggests that missing items can be estimated by a
single imputation method if they contribute to\50 % of a
given scale, and the imputation method is provided. If
C50 % of items comprising a scale are missing, then the
scale cannot be calculated and is regarded as missing.
Study outcomes
The primary outcome for this study was the PCS of the SF-
36, which was selected as it has been shown to be most
responsive to treatments that change physical morbidity
[43]. Secondary outcomes were the MCS and the 8 SF-36
scales. The PF scale, the main contributor to PCS, was
chosen as the key secondary outcome, as the developers of
the SF-36 tool emphasise that despite the strengths of the
component scores, they may not be as valid as a scale,
especially when differences are concentrated in one scale
[44].
Estimation of floor and/or ceiling effects
Floor and/or ceiling effects have been defined as present
when [15 % of the population score lowest or highest,
respectively, on a certain scale [32]. Floor and ceiling
effect estimations for each of the 8 SF-36 scales were based
on raw scores, as suggested by the manual [39]. For PCS
and MCS, the lowest possible score was arbitrarily
assumed to be either 10 or 20, as suggested by Taft et al.
[45].
Estimation of responsiveness to change
Responsiveness to change refers to the ability of a scale to
detect clinically important changes over time [32]. Its
estimation is based on comparing the smallest
detectable change (SDC), i.e. the smallest change which
exceeds the measurement error of the tool, to the MCID,
i.e. the smallest difference in a scale that patients perceive
to be beneficial [46]. A tool can only be deemed sensitive
to change if its MCID exceeds its SDC [32].
SDC was calculated using the formula: SDC ¼ 1:96p
2 SEM (where SEM is the standard error of mea-
surement) [32].
MCID can be estimated by a variety of methods, each
with its advantages and inherent limitations, as reviewed by
Crosby et al. [47]. Of those, we chose three methods which
could be applied to our data and planned to compare esti-
mations yielded by them. The method yielding the most
Qual Life Res (2016) 25:2799–2809 2801
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stringent criteria was planned to be selected for further
analyses. Anchor-based cross-sectional methods use a dif-
ference which is known to be clinically significant between
two populations at one point in time, in order to estimate
the minimal amount of change needed within one popula-
tion over time which would be clinically significant.
1. The anchor-based cross-sectional method of compar-
ison to disease-related criteria:
The extent to which SF-36 scales and summary mea-
sures reflect differences between known contrasting groups
was assessed following a method described by Cella et al.
[48] Contrasting groups were chosen if they had been
shown to influence SF-36 scores in the general English
population (age, gender, comorbidities) [34], or if they had
previously been shown to correlate with prognosis in this
study’s population (performance status, eGFR) [38]. We
used previously established assessment methods to quan-
tify these domains: Karnofsky performance scale (KPS)
[30, 49] for functional status, and both Charlson [50] and
Davies [51] scales for comorbidities. Further justification
for the use of those methods is provided elsewhere [35].
Groups were dichotomized across the median for each
scale and summary measure and compared using the
Mann–Whitney U test. Where significant differences were
found, means were adjusted to age and gender using an
ANCOVA model.
2. The anchor-based cross-sectional method of compar-
ison to a reference population:
We adjusted the method described by Jacobson and Truax,
which is based on the assumption that there is a population
which can be considered ‘functional’, i.e. normative, whereas
the study population at baseline is considered ‘dysfunctional’
[52]. Mean scores for the functional and dysfunctional pop-
ulations thus serve as anchors. A c value is calculated, beyond
which the test score would be closer to the normative popu-
lation mean than to the study mean. The equation is:
c ¼ S0M1þ S1M0ð Þ= S0þ S1ð Þ, when M0 and S0 are mean
and SD, respectively, for the normative (‘functional’) popu-
lation, and M1 and S1 are mean and SD, respectively, for the
study (‘dysfunctional’) population.We assumed that if a score
obtained over time in the study population is closer to that of
the ‘functional population’ at baseline than it is to the study
population at baseline, i.e. it is beyond the c value cut-off, then
this change is clinically significant. The amount of change can
only be calculated in relation to the anchors, but the direction
of change is irrelevant to its clinical significance; therefore,we
used the formula:
MCID ¼ studymeancj j
High-quality SF-36 data from people with less advanced
CKD were not available; therefore, WHS 2007 data for
people aged 75 and over were used as the normative
population [40]. Study SF-36 transformed (not normed)
scores were used for these comparisons. c value was
determined for each SF-36 scale, and MCID was calculated
using the equation above.
3. The distribution-based method based on SEM:
SEM, the standard error of measurement, is a sample-
independent measure which can be used to reflect a tool’s
accuracy, i.e. differentiate between a true difference in
scores and one that is due to measurement error [32]. It is
also used to calculate the SDC, which in turn can be
compared to the MCID to assess the tool’s responsiveness
to change. Not all authors consider the SDC, and some
have suggested that 1 SEM is an acceptable approximation
of the MCID [46, 48]. Based on previous data for SF-36,
[39] and on generally acceptable standards [32, 53], relia-
bility (r) in the current study was estimated using Cron-
bach’s alpha for internal consistency reliability. SEM was
estimated by the equation: SEM ¼ SDp 1 rð Þ.
MCID was estimated using baseline SF-36 data and then
re-estimated using the last available SF-36 data for each
participant.
Data analysis
IBM-SPSS version 22 was used for data analysis [54]. As
all data were not normally distributed, nonparametric
descriptive statistics and tests were used throughout the
analysis; however, as the tests compare means rather than
medians, both means and medians are reported. Differ-
ences between groups were regarded as statistically sig-
nificant if the two-tailed p value was smaller than 0.05. The
Bonferroni method of adjusting for multiple comparisons
was applied when primary comparisons yielded statisti-
cally significant results.
Results
38 men and 36 women were recruited. 51 of the 74 par-
ticipants (68.9 %) were of white ethnicity. Mean age was
80.7 (±6.8) years, and mean eGFR was 11.67 (±2.75) mL/
min/m2. Participants were followed up for a mean of 209
(±152.5) days (range 0–630 days) after enrolment. Base-
line characteristics of the study population appear in
Table 1.
SF-36 data were available for 73 participants (98.6 %).
There were no missing SF-36 items in the baseline mea-
surements used for the current analysis. Nine of 2628
(0.34 %) items were missing in the analysis of last avail-
able SF-36 data. The characteristics of the 8 SF-36 scales
and 2 summary measures at baseline are presented in
2802 Qual Life Res (2016) 25:2799–2809
123
Table 2. Floor and/or ceiling effects at baseline were
detected for 3 of the 8 scales (RP, RE and BP) and were not
detected for the summary measures PCS and MCS.
Mean baseline values of each SF-36 scale and summary
measure were compared by gender and across median
values for age, KPS, Davies comorbidity index, Charlson
comorbidity index and eGFR. For all scales and summary
measures, and following Bonferroni adjustment for those
six comparisons, mean scores were significantly different
across performance status groups. MCID (i.e. within-group
difference over time) was estimated as the difference
between those KPS means (at one point in time), adjusted
for age and sex (Table 3). Comparisons based on other
criteria yielded insignificant differences between groups (at
one point in time) and could therefore not be used to
estimate MCID.
Table 3 compares MCID estimations derived by the
different approaches: the anchor-based method based on
KPS, the anchor-based method using c values (with WHS
data as a comparative population) and MCID estimation
based on the distribution-based method (SEM and SDC)—
all using baseline data. As planned, we chose the method
yielding the most stringent criteria for our final estimation
of MCID. For PCS, MCID was thus estimated as 5.7
points, and for MCS MCID was estimated as 9.2 points.
SEMs were consistently smaller than anchor-based
estimations of MCID. Further, SDCs for five of the eight
scales (RP, BP, GH, VT and SF) were higher than MCIDs,
suggesting that those scales are not sensitive to change in
this study population. The summary scores PCS and MCS,
and the scales PF and MH were sensitive to change and
free from floor or ceiling effects in this population.
Re-estimation of floor and/or ceiling effect and MCID
using last available data for each of the 73 participants was
based on data collected a median of 29 days prior to last
contact (or median of 40 days prior to death in the 49
participants who died during the study). For all scales and
summary measures, mean and median scores were
Table 1 Baseline characteristics of the study population (N = 74)
Study site, N (%)
Site 1 34 (45.9)
Site 2 31 (41.9)
Site 3 9 (12.2)
Age (years)
Mean (SD) 80.7 (6.8)
Median (IQR) 81.4 (78.1–85.2)
Sex, N (%)
Male 38 (51.4)
Female 36 (48.6)
Ethnicity, N (%)
White 51 (68.9)
Black 12 (16.2)
South Asian 6 (8.1)
Other 5 (6.8)
eGFR
Mean (SD) 11.67 (2.75)
Median (IQR) 12.25 (9.73–14.18)
Davies comorbidity index, N (%)
Grade 0 14 (18.9)
Grade 1 44 (59.5)
Grade 2 16 (21.6)
Charlson comorbidity index
Mean (SD) 4.4 (2.06)
Median (IQR) 4.0 (3–5.25)
Karnofsky performance status
Mean (SD) 62 (11.2)
Median (IQR) 60 (50.0–70.0)
Table 2 Characteristics of SF-36 scales and summary measures at baseline (N = 73)
SF-36 scale Normed scores Raw scores
Mean (SD) Median (IQR) Possible range Observed range Floor/ceiling effects
Physical functioning 44.0 (6.4) 42.5 (39.4–47.2) 10–30 10–26 No
Role physical 44.6 (6.0) 45.3 (39.8–48.9) 4–20 4–17 Floor effect (19 % scored 4)
Bodily pain 53.6 (9.7) 52.4 (45.3–65.3) 2–12 3.2–12 Ceiling effect (30 % scored 12)
General health 41.2 (8.1) 41.4 (34.9–46.2) 5–25 5–21.4 No
Vitality 41.5 (8.7) 39.9 (34.3–48.2) 4–20 4–15 No
Social functioning 46.2 (8.7) 45.1 (41.3–52.7) 2–10 2–10 No
Role emotional 49.8 (8.9) 55.0 (42.8–57.4) 3–15 3–15 Ceiling effect (49 % scored 15)
Mental health 48.7 (9.8) 50.6 (44.0–56.0) 5–25 9–25 No
PCS 44.6 (5.8) 44.1 (40.9–47.8) N/A N/A No
MCS 48.1 (8.8) 49.8 (42.4–54.9) N/A N/A No
SD standard deviation, IQR inter-quartile range, PCS physical component summary (of SF-36), MCS mental component summary (of SF-36), N/
A not applicable
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significantly lower at this point compared to baseline (data
not shown). Floor and/or ceiling effects were observed for
5 scales (PF, RP, BP, VT and RE), but were not observed
for the summary measures PCS and MCS. Scores for all
scales and summary measures differed across KPS median.
Table 4 presents MCID, SEM and SDC values using last
available data. For PCS and MCS, SDCs and estimated
MCIDs were similar to those obtained using baseline data.
Discussion
This study provides a robust assessment of responsiveness
to change of SF-36, a widely used HRQoL assessment tool,
in a population of patients with stage 5 CKD. It shows that
whilst the usefulness of most SF-36 scales in assessing
HRQoL in this population, especially over time, is largely
limited by floor and/or ceiling effects or by poor respon-
siveness to change, the summary measures PCS and MCS
are sensitive to change and free from floor or ceiling
effects. For PCS, any change over time which is greater
than 5.7 points is likely to be clinically significant. For
MCS, this change must exceed 9.2 points.
SF-36 was originally designed as a HRQoL assessment
tool for populations with chronic uncomplicated medical
conditions [43, 55]. A particular concern was therefore that
in this population of patients with an advanced life-limiting
disease, substantial floor and/or ceiling effects would be
found. This was not demonstrated. In fact, floor and/or
ceiling effects at baseline were found for 3 scales: RP, RE
and BP, similar to previous reports in different populations,
including the one in which the tool was originally devel-
oped [55]. As the disease progressed though (measured
here by the last available data), floor effects were also
observed for the PF and VT scales, suggesting that in those
with a short life expectancy, SF-36 scales may not be able
to differentiate between the HRQoL of different individu-
als. The summary measures PCS and MCS did not, how-
ever, present a floor or ceiling effect in this population at
any time. They may therefore be a more appropriate out-
come measure in this population, yet must be considered in
the context of the scales from which they are derived.
A second concern regarding the appropriateness of SF-
36 in this population was its ability to detect clinically
significant change over time. Previous studies using SF-36
in patients with advanced CKD reported changes smaller
than 4 PCS points as statistically significant, without
commenting on its clinical significance [6, 7]. We used
several methods to specifically estimate the amount of
change which would be clinically significant to patients
Table 3 Summary of estimations of MCID using the anchor-based
and distribution-based approaches (with baseline data)
Comparison to
disease-related
criteria (KPS)
Comparison
to normative
dataa
SEM SDC
PCS 5.7 N/A 1.63 4.52
MCS 9.2 N/A 2.46 6.82
Physical functioning 7.9 7.4 2.24 6.21
Role physical 4.3 7.0 1.77 4.91
Bodily pain 7.1 5.2 2.71 7.51
General Health 8.2 9.2 3.61 10.01
Vitality 8.3 8.9 3.37 9.34
Social functioning 7.9 5.7 3.20 8.87
Role emotional 8.2 0.4 2.22 6.15
Mental health 9.7 1.3 3.42 9.48
KPS Karnofsky performance scale, SEM standard error of measure-
ment, SDC smallest detectable change, PCS physical component
summary, MCS mental component summary, N/A not applicable
a In this column, scores are transformed (0–100 scale) but not normed
Table 4 MCID, SEM and SDC
estimations using the last
available data (N = 73)
SF-36 scale MCID SEM SDC Responsiveness to changea Floor/ceiling effect
PCS 6.3 1.52 4.21 Yes None
MCS 8.7 2.54 7.03 Yes None
PF 7.6 1.94 5.38 Yes Floor effect
RP 6.1 1.71 4.75 Yes Floor effect
BP 7.6 2.10 5.83 Yes Ceiling effect
GH 7.5 3.52 9.75 No None
VT 9.0 3.00 8.32 Yes Floor effect
SF 7.1 4.04 11.20 No None
RE 6.0 2.26 6.26 No Ceiling effect
MH 11.3 3.85 10.66 Yes None
MCID minimal clinically important difference, SEM standard error of measurement, SDC smallest
detectable change
a Responsiveness to change was present if SDC\MCID
2804 Qual Life Res (2016) 25:2799–2809
123
(MCID), and compared it to the inherent accuracy of the
tool (SDC) in this population. Terwee et al. [32] argue that
for a tool to demonstrate acceptable responsiveness to
change, SDC must be smaller than MCID. Applying this
criterion, five of the eight SF-36 scales were found to be
not responsive to change in this population, and a sixth had
a ceiling effect at baseline. Therefore, only the summary
measures (PCS and MCS) and their key contributors (PF
and MH, respectively) provided acceptable data.
PCS and MCS were originally constructed in an attempt
to aggregate SF-36 scales that have similar factor content,
to simplify statistical testing and interpretation [44, 56].
Empirical data demonstrated their theoretical advantage in
increasing the number of levels defined, decreasing confi-
dence intervals, and eliminating floor and ceiling effects
[56]. Those findings were replicated in our population of
patients with advanced CKD, as demonstrated by freedom
from floor and/or ceiling effects and good responsiveness
to change for the summary measures. Importantly, results
for PF and MH, the key contributors to PCS and MCS,
respectively, mirror those of the summary measures,
implying that those 2 domains, whether measured by a
specific scale or by a summary measure, can be reliably
measured in this population over time. Unfortunately, other
domains of HRQoL (i.e. RP, BP, GH, VT, SF and RE)
were not as reliably measureable in this population by this
tool, as will be further discussed below.
Several methods were used to estimate the MCID. Of
those, the anchor-based method of comparison to func-
tional status produced the most stringent criteria, which
also appeared to best fit previous results: unlike other
potential anchors which were studied, baseline KPS scores
significantly correlated with baseline PCS (data not
shown). Previous studies of this population showed that
KPS deteriorated as death approached [57], as might rea-
sonably be expected for physical HRQoL. Estimating
MCID using normative data appeared to be less useful.
Since the same normative population was used for norming
SF-36 scores and for this analysis, transformed (not
normed) scores had to be used, and this limited compara-
bility to SDC estimations (which were performed using
normed scores) as well as to other populations. Also,
MCID for the summary scores, including this study’s pri-
mary outcome PCS, could not be estimated.
Given the popularity of SF-36 as a HRQoL assessment
tool in CKD and other populations, it is surprising that so
little has been reported of its MCID. Key publications by
the tool’s developers consistently avoided specifying any
MCID [43, 44, 56, 58], as does the publicly accessible
website (http://www.sf-36.org/). One user manual [59] was
cited by others to indicate that ‘differences of 5.7 and 6.3
points for PCS and MCS scores, respectively, significant at
the 95 % level, are considered clinically important’ [26].
We could not, however, obtain this manual to critically
appraise the data on which this claim was based. Interest-
ingly, for PCS this figure is identical to the estimation
produced here.
Some authors have made assumptions regarding MCID:
Luckett et al. [60] suggested that MCID should be 10 % of
any given scale, but accepted that this was arbitrary. Others
have chosen a 3–5 point difference as MCID for SF-36,
with little justification [61, 62]. A review aimed at devel-
oping MCIDs concluded that for SF-36, MCID for all
scales is 3–5 points, but this too was based on minimal data
of questionable quality [63]. Those assumptions may be too
lenient: Pagels et al. [3] showed that the mean difference in
PCS scores between patients with CKD stages 2–3 to that
of patients with CKD stages 4–5 was higher than 10 points,
which suggests that a clinically meaningful change over
time should at least match this figure. With a different
HRQoL tool, a 5–10 % difference in scores was associated
with ‘little’ patient-reported change over time, a 10–20 %
difference with ‘moderate’ change and[20 % difference
with ‘very much’ change [64]. Although this study was
performed in a different population (cancer patients), and
with a different tool (EORTC-QLQ-C30), its results do
highlight that a patient felt change in HRQoL may be much
larger than mean differences in scores which achieve sta-
tistical significance in a large sample.
Potential problems with focusing on MCIDs must be
acknowledged. A widely used definition of MCID is ‘the
smallest difference in score in the domain of interest which
patients perceive as beneficial and which would mandate, in
the absence of troublesome side effects and excessive cost, a
change in the patient’s management’ [65]. Quantitative
estimations of MCIDs, as described in our study, do not take
into account cost-effectiveness. Furthermore, MCID can
show significant between-population variation, even with
the same tool [66]. Also, authors often fail to account for the
impact of the chosen anchor (for anchor-based methods) or
the sample (for distribution-based methods) on the estimated
MCID [67]. Within-population variation was demonstrated
in this study when different estimation methods were used
and compared (Table 3). The magnitude of MCID may also
vary according to baseline status (e.g. small improvements
being more noticeable to those with poorer baseline
HRQoL) and the direction of change (improvement vs.
deterioration) [67, 68]. This was not accounted for in the
current study. Finally, it should be acknowledged that it may
be easier to demonstrate that a change of 3–5 points is
clinically meaningful than to prove that a change of 1–2
points is not [67]. On another level, we note that MCID is a
measure derived from populations, and as such, it averages
scores and eliminates inter-individual variance. It may
therefore not be suitable in assessing change in an individual
over time.
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A further limitation of this study is the choice of the
reference population for producing normed SF-36 scores.
As discussed, an ideal reference population was not
available, and compromise had to be accepted. The WHS
2007 data were chosen on the basis of having been col-
lected at a similar time to this study’s data collection, from
a British general population. However, an alternative ref-
erence population could have been derived from the Health
Survey for England 1996 [69, 70], which represented
English people at an earlier time. A brief examination of
this alternative reference population yielded overall lower
scores on all SF-36 scales and summary measures (data not
shown), suggesting that the choice of reference population
could have influenced the MCID estimations as well.
This study recruited a relatively small convenience
sample of conservatively managed individuals, who rep-
resent a minority of stage 5 CKD patients (10–20 % in the
three recruiting renal units) [35]. However, data com-
pleteness was very high, and statistically significant results
were obtained despite the use of highly conservative sta-
tistical methods (i.e. nonparametric tests and Bonferroni
adjustment to multiple comparisons). The use of
ANCOVA, a generally robust method to violations of
normality, only marginally changed the non-adjusted
results (data not shown). SEM is an inherently parametric
construct but in our data yielded a less stringent estimation
of MCID and was thus deemed less appropriate. That some
of our results are comparable to previously published
findings with SF-36 [55, 59] lends further strength to their
generalizability.
This study was not designed to determine whether SF-36
is a valid measure for HRQoL assessment in this popula-
tion of conservatively managed patients with stage 5 CKD.
One can presume that those patients may have similar
concerns to those of others with stage 5 CKD or to other
palliative care populations, although this was not specifi-
cally sought or demonstrated. In stage 5 CKD, patients
identified sexual functioning, body image, sleep and free-
dom or control as areas of importance [71, 72]. In palliative
and end of life care, existential concerns, comfort and
peace of mind were highlighted as important [73–75]. All
of those areas are not covered by SF-36. The content
validity of SF-36 as a generic tool has previously been
established, but it is recognized that it may miss content
areas of relevance to particular populations [43]. In CKD,
this led to the development of the KDQOL, a dialysis-
specific QoL questionnaire with an SF-36 core [71]. SF-36
was not previously used in the context of palliative care,
possibly because it does not address the unique concerns of
patients with advanced disease [76].
In conclusion, the appropriateness of SF-36 as a HRQoL
assessment tool in patients with stage 5 CKD is limited
both by its floor and ceiling effects and by its poor
responsiveness to change in this population. In addition, it
does not include domains which become increasingly
important as illness advances (such as existential concerns,
comfort and peace of mind). Only the summary measures
of SF-36, PCS and MCS, and their key contributors PF and
MH, respectively, can be used to assess changes in HRQoL
over time. The minimal amount of change which is likely
to be clinically meaningful is 5.7 for PCS and 9.2 for MCS,
which is much higher than that used in similar populations
so far.
Despite widespread use of SF-36 in patients with CKD,
a robust assessment of its responsiveness to change in this
population has never (to our knowledge) been reported.
This study adds such an assessment, and its results call into
question the usefulness of this outcome measure in this
population. We believe that this information will be valu-
able both in selecting HRQoL measures for future studies,
and for interpreting the findings of previous published
studies. Future research should focus on assessing the
validity of SF-36 in this population and should include
global measures most relevant to populations with
advancing illness, such as the Integrated Palliative Care
Outcome Scale [77, 78], alongside HRQoL measures. Such
an approach will open the door to research which could
determine the effectiveness of interventions (e.g. palliative
care) on the HRQoL of patients with stage 5 CKD.
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